BPC-157 Dosage Chart: Research Protocols by Body Weight & Goal

Key Points

• BPC-157 research dosing typically ranges from 200-800 mcg per day based on preclinical data
• Body weight calculations use approximately 2.5-10 mcg/kg from animal study translations
• Administration route (subcutaneous, intramuscular, or oral) affects protocol selection
• Research goals (tissue healing, gut health, systemic effects) influence dosing strategy
• Reconstitution volume determines concentration per syringe unit
• Most protocols use once or twice daily administration frequencies

Table of Contents

1. Introduction
2. BPC-157 Dosage Chart by Body Weight
3. Dosing by Research Goal
4. Administration Routes Comparison
5. Reconstitution Guide
6. Injection Frequency Protocols
7. Protocol Duration Guidelines
8. Frequently Asked Questions
9. Conclusion
10. References

Introduction

BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide that has been studied extensively in preclinical research for its effects on tissue repair mechanisms. For a comprehensive overview of this peptide's properties and research, see our BPC-157 complete guide. Determining appropriate research dosing requires understanding the relationship between body weight, administration route, and research objectives.

This BPC-157 dosage chart provides researchers with comprehensive reference tables derived from published animal studies. The dosing ranges presented here represent translations from preclinical data and are intended for research planning purposes only.

Important: BPC-157 is not approved for human therapeutic use. All dosing information reflects preclinical research protocols and should be interpreted within that context.

BPC-157 Dosage Chart by Body Weight

The following BPC-157 dosage chart provides weight-based calculations using the commonly referenced range of 2.5-10 mcg/kg body weight, derived from allometric scaling of animal research data.

Standard Research Dosage Chart

Simplified Daily Dosage Reference

For practical research applications, many protocols use fixed dosing ranges rather than precise weight-based calculations:

Dose Selection Considerations

Factors influencing dose selection:

• Research objective: Targeted vs. systemic effects may require different approaches
• Subject characteristics: Body composition and metabolic factors
• Protocol duration: Shorter protocols may use higher doses
• Administration route: Oral administration may require adjusted dosing
• Combination protocols: Concurrent compounds may affect dosing decisions

Dosing by Research Goal

Different research objectives may warrant different BPC-157 dosing strategies. The following recommendations are based on patterns observed in published preclinical literature.

Tissue Healing Research (Musculoskeletal Focus)

For tendon, ligament, muscle, and bone healing research:

Research context: Studies examining tendon healing (Chang et al., 2011) and muscle repair (Staresinic et al., 2006) documented effects using injectable protocols in this dose range equivalent.

Gut Health Research (Gastrointestinal Focus)

For gastric protection, intestinal healing, and GI-focused research:

Research context: BPC-157's origin as a gastric peptide fragment makes oral administration particularly relevant for GI research applications. Multiple studies demonstrate oral efficacy for gastrointestinal endpoints (Sikiric et al., 2011).

Systemic Research (General/Multi-System)

For research examining systemic effects, neurological endpoints, or cardiovascular parameters:

Research context: Systemic effects documented in research include NO pathway modulation and angiogenesis promotion, which may benefit from injectable administration for consistent tissue delivery.

Comparison Table by Research Goal

Administration Routes Comparison

BPC-157 can be administered through multiple routes, each with distinct characteristics affecting dosing decisions.

Subcutaneous Injection (SubQ)

The most common administration method in peptide research:

Dosing adjustment: Standard doses apply; no adjustment typically needed.

Intramuscular Injection (IM)

Direct injection into muscle tissue:

Dosing adjustment: Standard doses apply; may achieve faster peak levels.

Oral Administration

Unique to BPC-157 among most peptides due to gastric stability:

Dosing adjustment: Some protocols increase oral doses by 50-100% to account for lower systemic bioavailability. However, for GI-targeted research, standard doses may suffice due to direct local contact.

Route Comparison Summary

Reconstitution Guide

Proper reconstitution is essential for accurate BPC-157 dosing. The following tables provide quick reference calculations for common vial sizes.

5 mg BPC-157 Vial Reconstitution Chart

10 mg BPC-157 Vial Reconstitution Chart

Quick Dose-to-Units Calculator

For a 5 mg vial reconstituted with 2 mL BAC water (25 mcg/unit):

For detailed reconstitution instructions and our interactive calculator, see our complete peptide reconstitution guide. For deeper understanding of how BPC-157 produces its effects, see our article on BPC-157 mechanism of action.

Injection Frequency Protocols

Research protocols vary in administration frequency. The following outlines common approaches documented in preclinical literature.

Once Daily (QD) Protocol

Example Protocol:

• Dose: 300-500 mcg
• Timing: Morning or evening (consistent)
• Duration: 4-8 weeks

Twice Daily (BID) Protocol

Example Protocol:

• Dose: 150-250 mcg per injection (300-500 mcg total)
• Timing: Morning and 8-12 hours later
• Duration: 4-8 weeks

Comparison: QD vs BID Dosing

Frequency Selection Factors

Consider these factors when selecting injection frequency:

1. Research objective: Acute vs. sustained effects
2. Half-life considerations: BPC-157 has relatively short plasma half-life
3. Practical constraints: Subject availability and compliance
4. Protocol precedent: Match published study methodology
5. Total daily dose: Higher doses may benefit from splitting

Protocol Duration Guidelines

Research protocol duration varies based on objectives and the nature of investigation.

Duration by Research Application

Cycle Considerations

While long-term BPC-157 research data is limited, some protocols incorporate:

• Continuous protocols: Daily administration throughout study period
• Pulsed protocols: Periods of administration followed by rest periods
• Loading protocols: Higher initial doses followed by maintenance

Note: Optimal protocol duration has not been established for any application. Duration should be determined by research objectives and safety considerations.

Frequently Asked Questions

What is the most common BPC-157 research dose?

Based on preclinical literature translations, 250-500 mcg daily is the most commonly referenced research range. This corresponds to approximately 5-10 mcg/kg body weight in animal study equivalents.

Should BPC-157 dose be based on body weight?

Weight-based dosing (mcg/kg) provides a standardized approach, though many protocols use fixed doses within the 200-500 mcg range. For research standardization, weight-based calculations may improve reproducibility.

Is oral BPC-157 dosing different from injectable?

Some protocols increase oral doses to account for lower systemic bioavailability. However, for GI-targeted research, standard doses may provide adequate local effects due to direct mucosal contact.

How long do BPC-157 research protocols typically last?

Most published research protocols range from 2-8 weeks, with 4-6 weeks being common for tissue healing studies. Duration depends on research objectives and model characteristics.

Can BPC-157 be taken once daily?

Yes, both once daily (QD) and twice daily (BID) protocols appear in research literature. Once daily offers convenience, while twice daily may provide more consistent peptide levels throughout the day.

What is the difference between low and high dose protocols?

Low doses (200-300 mcg) are typically used for maintenance or conservative protocols. Higher doses (500-800 mcg) may be used for acute or intensive research phases. Dose selection should align with research objectives.

Conclusion

This BPC-157 dosage chart provides researchers with comprehensive reference data for protocol planning. Key takeaways include:

• Weight-based dosing ranges from 2.5-10 mcg/kg, translating to approximately 200-800 mcg daily for most subjects
• Research goals influence dosing strategy, with tissue healing, gut health, and systemic protocols having distinct approaches
• Administration route affects protocol design, with subcutaneous injection offering high bioavailability and oral dosing providing GI-targeted effects
• Reconstitution calculations determine the volume needed to achieve desired dose concentrations
• Injection frequency (once or twice daily) depends on research objectives and practical considerations

All dosing information presented here derives from preclinical research data and is intended for research planning purposes only. BPC-157 remains a research compound without FDA approval for therapeutic use.

References

1. Sikiric P, Seiwerth S, Rucman R, et al. Stable gastric pentadecapeptide BPC 157: Novel therapy in gastrointestinal tract. Curr Pharm Des. 2011;17(16):1612-1632. doi:10.2174/138161211796196954

2. Chang CH, Tsai WC, Lin MS, et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol. 2011;110(3):774-780. doi:10.1152/japplphysiol.00945.2010

3. Staresinic M, Petrovic I, Novinscak T, et al. Effective therapy of transected quadriceps muscle in rat: Gastric pentadecapeptide BPC 157. J Orthop Res. 2006;24(5):1109-1117. doi:10.1002/jor.20089

4. Sikiric P, Seiwerth S, Rucman R, et al. Brain-gut axis and pentadecapeptide BPC 157: Theoretical and practical implications. Curr Neuropharmacol. 2016;14(8):857-865. doi:10.2174/1570159X13666160502153022

5. Klicek R, Sever M, Radic B, et al. Pentadecapeptide BPC 157, in clinical trials as a therapy for inflammatory bowel disease (PL14736), is effective in the healing of colocutaneous fistulas in rats. Inflamm Bowel Dis. 2008;14(11):1517-1522. doi:10.1002/ibd.20525

6. Seiwerth S, Rucman R, Turkovic B, et al. BPC 157 and standard angiogenic growth factors: Gastrointestinal tract healing, lessons from tendon, ligament, muscle and bone healing. Curr Pharm Des. 2018;24(18):1972-1989. doi:10.2174/1381612824666180712110447

7. Hsieh MJ, Liu HT, Wang CN, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med. 2017;95(3):323-333. doi:10.1007/s00109-016-1488-y

8. Reagan-Shaw S, Nihal M, Ahmad N. Dose translation from animal to human studies revisited. FASEB J. 2008;22(3):659-661. doi:10.1096/fj.07-9574LSF